True Leaf Brands Inc. Condensed Interim Consolidated Financial Statements For the Nine Months ended December 31, 2019 and 2018

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

Condensed Interim Consolidated Statements of Financial Position

(Unaudited)

(Expressed in Canadian dollars)

	Notes	Dec	cember 31, 2019	March 31, 2019		
Assets						
Current						
Cash and cash equivalents		\$	410,574	\$	4,391,072	
Short-term investments			57,500		57,500	
Trade and other receivables	5		593,141		632,223	
Inventories	6		993,529		332,088	
Prepaid expenses and deposits	7		191,804		417,243	
			2,246,548		5,830,126	
Land	8		3,380,387		3,380,387	
Property, plant and equipment	8		7,846,122		7,730,894	
Intangible assets	9		163,770		155,508	
Other assets	10	\$	250,000	\$	250,000	
Total assets			13,886,827		17,346,915	
Liabilities						
Current						
Accounts payable and accrued liabilities		\$	1,465,641	\$	1,635,337	
Construction holdback payable	8		-		24,492	
Current portion convertible note payable	10		2,800,000		2,000,000	
Total current liabilities			4,265,641		3,659,829	
Convertible note payable	10		1,844,523		1,808,056	
Total liabilities			6,110,164		5,467,885	
Shareholders' equity						
Share capital	12		23,781,463		22,689,173	
Reserves			4,331,781		3,660,877	
Accumulated other comprehensive income			41,874		-,,,-	
Deficit			(20,378,455)		(14,471,020)	
Total shareholders' equity			7,776,663		11,879,030	
Total liabilities and shareholders' equity		\$	13,886,827	\$	17,346,915	

Nature of operations and going concern (Note 1)

Commitments (Note 17)

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Unaudited)

(Expressed in Canadian dollars)

	Notes	For the Months Deceming 2019	Enc	ded	For the Months December 2019	Enc	led
Sales		\$ 491,040	\$	652,370	\$ 1,612,449	\$	1,715,775
Cost of sales		(321,678)		(368,661)	(880,124)		(944,897)
Gross profit		169,362		283,709	732,325		770,878
Operating Expenditures							
Accretion expense	10	264,973		-	836,467		-
Administrative and office	13	1,160,786		907,801	3,431,130		2,378,413
Amortization and depreciation	8,9	73,179		3,744	121,372		119,618
Research and development		15,832		74,992	55,161		114,557
Selling and marketing	14	366,312		508,660	1,420,224		1,350,480
Share-based compensation	12	294,795		133,828	768,473		455,477
Total operating expenditures		2,175,877		1,629,025	6,632,827		4,418,545
Loss from operations		(2,006,515)		(1,345,316)	(5,900,502)		(3,647,667)
Other income		6,565		34,300	53,990		60,531
Foreign exchange gain (loss)		(10,358)		(1,073)	(60,923)		79,061
Loss and comprehensive loss for the year		\$ (2,010,308)	\$	(1,312,089)	\$ (5,907,435)	\$	(3,508,075)
Loss per common share – basic		(\$0.02)		(\$0.01)	(\$0.06)		(\$0.04)
Weighted average number of common shares outstanding – basic		100,998,179		95,473,604	100,062,911		95,473,604

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(Unaudited)

(Expressed in Canadian dollars)

					cumulated other			
				(comprehensive		Total	Shareholders'
	Number of Shares	Share Capital	Reserves		income	Deficit		Equity
Balance, March 31, 2018	95,369,059	\$ 21,693,918	\$ 2,518,723	\$	- \$	(8,961,872)	\$	15,250,769
Shares issued on exercise of stock options	857,145	240,001	(81,429)		-	-		158,572
Shares issued on exercise of warrants	60,000	27,000	-		-	-		27,000
Shares issued to executive	100,000	42,000	-		-	-		42,000
Share-based compensation	-	-	413,477		-	-		413,477
Loss for the period	-	-	-		-	(3,508,075)		(3,508,075)
Balance, December 31, 2018	96,386,204	\$ 22,002,919	\$ 2,850,771	\$	- \$	(12,469,947)	\$	12,383,743
Balance, March 31, 2019	97,954,521	\$ 22,689,173	\$ 3,660,877	\$	- \$	(14,471,020)	\$	11,879,030
Shares issued on exercise of stock options	700,000	418,600	(142,100)		-	-		276,500
Shares issued on exercise of warrants	1,507,578	521,190	-		-	-		521,190
Shares issued to executive	916,666	152,500	-		-	-		152,500
Share-based compensation	-	-	813,004		-	-		813,004
Foreign operations currency translation differences	-	-	-		41,874	-		41,874
Loss for the period	-	-	-		-	(5,907,435)		(5,907,435)
Balance, December 31, 2019	101,078,765	\$ 23,781,463	\$ 4,331,781	\$	41,874 \$	(20,378,455)	\$	7,776,663

Condensed Interim Consolidated Statements of Cash Flows

(Unaudited)

(Expressed in Canadian dollars)

	Nine Months ended December 31,			
	2019	2018		
Operating activities				
Loss for the period	(\$5,907,435)	(\$3,508,075)		
Items not affecting cash:				
Accretion expense	836,467	-		
Amortization and depreciation	121,370	119,618		
Share-based compensation	768,473	455,477		
Inventory write-down	-	46,733		
Changes in non-cash working capital items:				
Prepaid expenses and deposits	225,439	(112,079)		
Accounts payable and accrued liabilities	(194,188)	(119,917)		
Due to related parties	-	(6,783)		
Inventories	(661,441)	109,615		
Trade and other receivables	39,082	(227,677)		
Net cash used in operating activities	(\$4,772,233)	(\$3,243,088)		
Investing activities				
Additions to property, plant and equipment	(200,899)	(5,292,548)		
Intangible asset costs	(43,965)	(76,668)		
Net cash used in investing activities	(\$244,864)	(\$5,369,216)		
Financing activities				
Proceeds from exercise of options	276,500	158,572		
Proceeds from share issue	152,500	-		
Proceeds from exercise of warrants	521,190	27,000		
Net cash provided by financing activities	950,190	185,572		
Change in cash and cash equivalents for the period	(\$4,066,907)	(\$8,426,732)		
Effect of foreign exchange	86,409	- -		
Cash and cash equivalents, beginning of the period	4,391,072	10,812,815		
Cash and cash equivalents, end of the period	\$410,574	\$2,386,083		

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

True Leaf Brands Inc. (formerly True Leaf Medicine International Ltd.) (the "Company" or "True Leaf") was incorporated under the Business Corporations Act of the Province of British Columbia on June 9, 2014 and is the legal parent of True Leaf Investments Corp. ("TL Investments"), True Leaf Cannabis Inc. ("TL Cannabis"), True Leaf Pet Inc. ("TL Pet") and True Leaf Pet Europe LLC Sàrl ("TL Pet Europe").

On May 21, 2019 the Company changed the name of True Leaf Medicine International Ltd. To True Leaf Brands Inc., and changed the name of its subsidiary, True Leaf Medicine Inc., to True Leaf Cannabis Inc. The legal and organizational structure was not altered as part of these name changes.

The Company's shares trade on the Canadian Securities Exchange (the "CSE") under the symbol "MJ", the OTC Market Group's OTCQX International Market under the ticker symbol "TRLFF" and the Frankfurt Stock Exchange under the symbol "TLA". The Company's head office and registered office is located at 200, 1238 Homer Street, Vancouver, BC, V6B 2Y5.

The Company manufactures and distributes hemp-based nutrition for pets. TL Pet and TL Pet Europe have entered the Canadian, US and European natural pet product market with a product line consisting of hemp functional chews and supplemental products for pets.

The Company has received approval to become a licensed producer of medicinal cannabis for the Canadian market under the new Cannabis Act and has secured three licenses from Health Canada to cultivate, process and sell medical cannabis.

Going Concern

These condensed interim consolidated financial statements (the "financial statements") have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business.

For the period ended December 31, 2019, the Company incurred a comprehensive loss of \$5,907,435 and has a deficit of \$20,378,455. The Company earned revenues of \$1,554,844 (2018 - \$1,715,775) from TL Pet and TL Pet Europe, however, these two subsidiaries have not yet achieved profitability.

On February 21, 2019, the Company closed a financing which raised gross proceeds of \$4,500,000. After fees and other expenses, the financing provided net proceeds of \$4,242,204 which included \$250,000 to be set aside in a restricted cash reserve account.

Additional financing may be required in the future for management to pursue its strategic objectives and there can be no assurances that the Company will be successful in obtaining additional financing. If the Company is unable to raise the necessary financing and generate sufficient cash flows to meet obligations as they come due, the Company may, at some point, be required to reduce its operations. As such, there are material uncertainties that raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue operations.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

2. BASIS OF PREPARATION

(a) Statement of compliance

These condensed interim consolidated financial statements are unaudited and have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IASB") ("IFRS") as applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting. These condensed interim consolidated financial statements were approved by the Company's Board of Directors on February 27, 2020.

(b) Principles of consolidation

These financial statements incorporate the financial statements of the Company and its controlled subsidiaries. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. These financial statements include the accounts of the Company and its whollyowned subsidiaries: TL Investments, TL Cannabis, TL Pet and TL Pet Europe. All intercompany transactions and balances have been eliminated on consolidation.

(c) Basis of measurement

These financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value (Note 15). The accounting policies set out below have been applied consistently to all periods presented in these financial statements with the exception of the change in accounting policies noted below.

3. CHANGES IN ACCOUNTING POLICIES

Adoption of New IFRS Pronouncements

IFRS 16 – Leases

IFRS 16 Leases was issued in January 2016 and is effective for periods beginning on or after January 1, 2019. The new standard eliminates the classification of leases as either operating or finance leases. It provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value.

Effective April 1, 2019, the Company has adopted IFRS 16. On transition, the Company has elected to apply the recognition exemptions on short-term leases and low-value leases. The adoption of IFRS 16 did not have a material impact on the Company's consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

4. USE OF ESTIMATES AND JUDGMENTS

The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the period. These estimates are, by their nature, uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(a) Estimates

Critical accounting estimates are estimates and assumptions made by management that may result in a material adjustment to the carrying amount of assets and liabilities include, but are not limited to, the following:

• Share-based payments and compensation

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating the fair value for share-based payment transactions and the resulting share-based compensation expense is based on a variety of assumptions, including the expected life, risk-free interest rates, volatility, and forfeiture rates.

• Amortization rates for intangible assets

Amortization expenses are calculated based on assumed intangible asset lives. Should the intangible asset life or amortization rates differ from the initial estimate, an adjustment would be made in the consolidated statement of loss and comprehensive loss.

• Valuation of convertible note

At the issue date of the convertible note, the fair value of the liability component was estimated using the prevailing market interest rates for similar non-convertible instruments for the Company. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion, buyback, or on the instrument's maturity date.

(b) Critical judgements

Information about critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the condensed interim consolidated financial statements include, but are not limited to, the following:

Functional currency

The functional currency of each of the Company's subsidiaries is the currency of the primary economic environment in which the entity operates. Determination of the functional currency may involve certain judgments to determine the primary economic environment and the Company reconsiders the functional currency of its entities if there is a change in events and conditions which determined the primary economic environment.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

5. RECEIVABLES

	December 31, 2019	March 31, 2019
Trade receivables (a)	\$ 142,939	\$ 217,462
Miscellaneous receivables (b)	256,061	109,832
Goods and services tax receivable	194,142	304,929
	\$ 593,141	\$ 632,223

(a) Trade receivables

Trade receivables are non-interest bearing and are due within 30 days. As at December 31, 2019, the Company had \$874 in trade receivables that were over 90 days (March 31, 2019 - Nil).

During the nine months ended December 31, 2019, revenues from three distributors amounted to 29% of total sales (March 31, 2019: 40%). As at December 31, 2019, these top three distributors amounted to 55% of total trade receivables (March 31, 2019: 34%).

(b) Miscellaneous receivables

At December 31, 2019, certain management and a director were indebted to the Company \$174,229 (March 31, 2019: \$72,335) for withholding taxes remitted on their behalf in connection with common shares issued as an employment benefit and director fees paid. The balance is non-interest bearing. Miscellaneous receivables also included an amount of \$51,920 (March 31, 2019: \$37,497) in connection with rent receivable.

6. INVENTORY

	December 31, 2019	March 31, 2019
Finished goods	\$797,860	\$173,410
Supplies	195,670	158,678
	\$993,529	\$332,088

The cost of inventories recognized as an expense in the nine months ended December 31, 2019 was \$364,567 and is included in cost of sales (2018: \$415,921).

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

7. PREPAID EXPENSES AND DEPOSITS

	December 31, 2019	March 31, 2019
Insurance premiums	\$13,671	\$156,636
Property Tax	· -	-
Other	35,709	124,804
Prepaid expenses	49,381	281,440
Construction deposits	134,021	128,077
Security deposits	8,402	7,726
	142,423	135,803
	\$191,804	\$417,243

As at December 31, 2019, prepaid expenses include a deposit of \$134,021 (March 31, 2019 - \$128,077) paid in connection with construction of the Company's cannabis production facility in Lumby (Note 7). The deposit is refundable subject to approval by the Village of Lumby that the Company has complied with conditions set out in its various permits. Subsequent to December 31, 2019, the Company received \$28,000 as a refund.

8. PROPERTY, PLANT AND EQUIPMENT

Cost:	Build	lings	asehold covement	-	Office miture	Equ	ipment	Т	Cotal
Balance, March 31, 2018	\$ 7	26,955	\$ 79,929	\$	20,165	\$	49,716	\$	876,765
Additions	6,7	79,214	_		-		146,168		6,925,382
Balance, March 31, 2019	7,5	06,169	79,929		20,165		195,884		7,802,147
Additions		78,343	11,246		6,277		105,033		200,899
Balance December 31, 2019	\$ 7,5	84,512	\$ 91,175	\$	26,442	\$	300,916	\$	8,003,044
Accumulated depreciation:									
Balance, March 31, 2018	\$	-	\$ 9,101	\$	2,150	\$	6,139	\$	17,390
Depreciation for the year		-	31,972		8,066		13,825		53,863
Balance, March 31, 2019		-	41,073		10,216		19,964		71,253
Depreciation for the period		47,403	8,554		4,818		24,896		85,671
Balance December 31, 2019	\$	47,403	\$ 49,627	\$	15,034	\$	44,860	\$	156,922
Carrying value:									
As at March 31,2019	\$ 7,5	06,169	\$ 38,856	\$	9,949	\$	175,920	\$	7,730,894
As at December 31, 2019	\$ 7,5	37,109	\$ 41,548	\$	11,408	\$	256,057	\$	7,846,122

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

8. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

During the year ended March 31, 2018, the Company acquired a 40 acre property located in Lumby, B.C. for total consideration of \$3,380,387 to build its cannabis cultivation facility, which is classified as land in the statement of financial position.

Construction of the Company's building was completed in March 2019, with total construction costs being capitalized until the building is ready for its intended use as a licensed producer and grower of cannabis under the Cannabis Act. In November 2019, the Company received approval to be a licensed producer of medicinal cannabis and, as such, the facility is fully employable and depreciation of the facility commenced.

9. INTANGIBLE ASSETS

Cost:	Website	Trademarks and related costs	Intellectual property	Total
Balance, March 31, 2018	\$10,801	\$117,400	\$55,500	\$183,701
Additions	-	83,108	-	83,108
Balance, March 31, 2019	10,801	200,508	55,500	266,809
Additions	7,012	36,953	-	43,965
Balance, December 31, 2019	\$17,813	\$237,461	\$55,500	\$310,774
Accumulated amortization:				
Balance, March 31, 2018	\$9,956	\$17,180	\$13,875	\$41,011
Amortization for the year	845	47,245	22,200	70,290
Balance, March 31, 2019	10,801	64,425	36,075	111,301
Amortization for the period Effect of foreign exchange	-	26,892	8,811	35,703
Balance, December 31, 2019	\$10,801	\$91,317	\$44,886	\$147,004
Carrying value:				
As at March 31, 2019	-	\$136,083	\$19,425	\$155,508
As at December 31, 2019	\$7,012	\$146,144	\$10,614	\$163,770

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

10. CONVERTIBLE NOTES

On February 21, 2019, the Company completed a private placement of secured convertible notes for gross proceeds of \$4,500,000, of which \$250,000 is set aside in cash in a restricted bank account, and classified as other asset pursuant to the terms of the Convertible Security Funding Agreement ("CSFA"). The maturity date of the debenture is February 21, 2021. Upon maturity, the Company is required to repay \$5,400,000, consisting of the principal amount of \$4,500,000 (the Principal) plus interest costs of \$900,000. The Company has the right to buy-back the convertible note at any time. If the Company repays the note prior to February 21, 2020, the repayment amount is reduced to \$4,950,000, consisting of the Principal of \$4,500,000 plus \$450,000 of interest costs. The Company is required to repay the principal amount in 18 equal monthly installments commencing August 21, 2019, with the interest payment of \$900,000 due upon maturity, subject to the reduction of interest described above.

The note is convertible, at a fixed conversion price of \$0.40 per common share (the "conversion price"), at the option of the holder, into common shares of the Company at any time over the term of the note or if a change of control occurs. Should the Company elect to buy-back all or a portion of the convertible note, the investor has the right to convert to common shares 25% of the principal amount of the note that the Company is buying back, at the same fixed conversion price. In addition, the investor has the right, on each 90-day period to elect payment of quarterly accrued interest in the form of common shares at the then current share price. Any interest paid via common shares will reduce the cash interest payment obligation required at debenture maturity upon early repayment.

The investor also received 5,625,000 warrants as part of this convertible debenture, entitling the investor to purchase one common share at an exercise price of \$0.5089 for a period of 36 months from the issue date. The warrants are subject to acceleration where 50% of the total warrants outstanding, or 2,812,500 warrants, may be accelerated at the option of the Company if the volume weighted average price ("VWAP") of the Company's common shares are at least \$1.0178 for 30 consecutive trading days. The remaining warrants may be accelerated by the Company if the VWAP of the Company's common shares are at least \$1.5267 for 30 consecutive trading days.

The Company allocated the gross proceeds from the issuance between the estimated fair value of the debt and equity components using the residual method. The Company used an effective annualized discount rate of 17.2%, which resulted in valuation of the debt component at \$4,303,813 and the equity component at \$196,187 before issue costs. The debt component is measured at amortized cost.

Allocation of gross proceeds and balance of debt component:	December 31, 2019
Gross proceeds of issued debentures - maturing February 21, 2021	\$ 4,500,000
Less: allocation to equity for debt to share conversion option	(196,187)
Less: allocation to equity for fair value of warrants	(399,998)
Less: transaction costs	(257,796)
Accretion of debenture discount	962,518
Issue costs allocated to equity	35,986
Total	\$ 4,644,523
Current portion of debentures	\$ 2,800,000
Long-term portion	\$ 1,844,523

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

10. **CONVERTIBLE NOTES (continued)**

During the nine months ended December 31, 2019, the Company recorded accretion expense of \$836,467 (2018: \$nil) relating to this convertible debt.

On October 7, 2019, the Company completed a waiver, amendment and funding agreement supplement (the "Waiver") for the CSFA noted above. Pursuant to the terms of the CSFA, the Company was required to repay the principal amount in 18 equal monthly installments (\$250,000) commencing August 21, 2019. The Waiver provides for (i) a 6 month deferral of these \$250,000 payments to the Investor to March 22, 2020; (ii) the issuance of an additional convertible security with a face value of \$540,000 (the "Deferral Convertible Security") to the Investor; and (iii) the issuance of 2,160,000 warrants ("New Warrants") of the Company to the Investor.

The Deferral Convertible Security is convertible into common shares of the Company at a conversion price of \$0.21 per share. The Deferral Convertible Security is required to be repaid in 18 equal monthly installments (\$30,000) beginning on March 22, 2020, except that the repayment amount will be reduced in any month by any amount converted by the Investor into the Company's common shares. The New Warrants entitle the Investor to purchase one common share for each warrant, at an exercise price of \$0.21, for a period of 36 months from the date of issue.

As at December 31, 2019, the current portion of the original convertible note, after giving effect to the transactions within the Waiver, is 2,800,000 (\$2,500,000 on the original convertible note and \$300,000 on the new convertible note).

11. RELATED PARTY BALANCES AND TRANSACTIONS

a) Goods and services

The Company had the following transactions with related parties during the nine months ended December 31, 2019 and 2018 which were recognized at the amounts that were agreed upon between the two parties:

	Nine Months Ended December 31,		
	2019	2018	
Paid or payable to the Chief Executive Officer for office space rental	\$49,825	\$22,500	
Paid or payable to a company controlled by its Chief Executive Officer for costs associated with packaging inventory	\$306,951	\$75,891	

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

11. RELATED PARTY BALANCES AND TRANSACTIONS (CONTINUED)

b) Compensation of key management personnel

The Company considers its key management personnel to be its Directors, Chief Executive Officer, Chief Financial Officer and other senior executives including the President of True Leaf Pet and SVP of Operations of True Leaf Pet.

	Nine Months Ended	l December 31,
	2019	2018
Director compensation (non-Executive):		
Salaries and consulting fees	\$ 45,229	\$ 59,375
Share-based compensation	13,661	110,771
	\$ 58,890	\$170,146
Management compensation:		
Salaries and management fees	\$ 539,625	\$ 168,733
Share-based compensation	152,500	149,321
	\$ 692,125	\$318,054
	\$ 747,786	\$448,200

c) Amounts due from key management and a current director of \$174,229 are included in accounts receivable at December 31, 2019 (March 31, 2019: \$72,335) and are unsecured and non-interest bearing.

12. SHARE CAPITAL

a) Authorized

Unlimited Common voting shares with no par value

b) Issued

The Company had the following share capital transactions during the nine-month period ended December 31, 2019:

- a. The Company issued 1,507,578 common shares pursuant to the exercise of share purchase warrants for gross proceeds of \$521,190.
- b. The Company issued 700,000 common shares pursuant to the exercise of share options for proceeds of \$276,500.
- c. The Company issued 916,666 common shares to an executive as part of their employment contract and recorded \$152,500 as a share-based compensation expense, with the same amount as an addition to share capital.

The Company did not have any share capital transactions during the nine-month period ended December 31, 2018.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

12. SHARE CAPITAL (CONTINUED)

c) Share purchase warrants

Share purchase warrant transactions are summarized as follows:

		Number of Warrants	W'ted Ave. Exercise Price \$
Balance, March 31, 2018		6,297,380	0.49
	Warrants exercised	(1,128,317)	0.36
	Warrants issued	5,625,000	0.51
Balance, March 31, 2019		10,794,063	0.51
	Warrants expired	(2,804,342)	0.43
	Warrants exercised	(1,507,578)	0.37
	Warrants issued	2,160,000	0.21
Balance, December 31, 2019		8,642,143	0.49

As at December 31, 2019, the following share purchase warrants are outstanding:

Number of Warrants	Price(\$)	Expiry Date
857,143	1.05	21-Nov-20
5,625,000	0.51	21-Feb-22
2,160,000	0.21	22-Mar-22
8,642,143		

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

12. SHARE CAPITAL (CONTINUED)

d) Stock options

The Company has a Stock Option Plan (the "Plan") in place under which it is authorized to grant options to directors, executive officers, employees and consultants enabling them to acquire up to 10% of the issued and outstanding common shares of the Company in any twelve-month period. Under the Plan, the exercise price of each stock option is subject to a minimum of \$0.10 and may not be less than the closing market price of Company's common shares on the trading day immediately preceding the date of grant of the options. The options can be granted for a maximum term of five years and vest at the discretion of the Board of Directors.

Stock option transactions are summarized as follows:

		Number of Options	W'ted Ave. Exercise Price \$
Balance, March 31, 2018		5,907,145	0.55
	Stock options exercised	(857,145)	0.19
	Stock options granted	4,410,000	0.56
	Stock options forfeited	(1,635,000)	0.67
Balance, March 31, 2019		7,825,000	0.57
	Stock options granted	1,085,000	0.29
	Stock options exercised	(700,000)	0.40
	Stock options expired	(1,550,000)	0.40
	Stock options forfeited	(275,000)	0.56
Balance, Decemb	per 31, 2019	6,385,000	0.58

As at December 31, 2019, the following stock options are outstanding and exercisable:

Number of Options	Exercise Price		Expiry Date
Outstanding	Exercisable	(\$)	
100,000	100,000	0.94	February 6, 2020
1,075,000	1,000,000	0.94	February 6, 2023
725,000	491,666	0.50	July 31, 2023
1,050,000	350,000	0.56	September 10, 2023
1,600,000	300,000	0.56	March 6, 2024
750,000	-	0.61	March 21, 2024
1,085,000	50,000	0.29	July 25, 2024
6,385,000	2,291,666		

During the nine months ended December 31, 2019, the Company recorded share-based compensation of \$615,973 (2018: \$321,649) relating to the stock options.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

13. ADMINISTRATIVE AND OFFICE EXPENSE

	Three months end	Three months ended December		
	31,		December 31,	
	2019	2018	2019	2018
Accounting and legal	\$ 230,569	\$ 100,174	\$ 381,571	\$ 253,802
Application cost	-	18,435	3,419	50,235
Director fees	5,235	7,250	45,229	14,375
Filing fees	27,094	4,781	51,708	27,481
Insurance	46,371	57,851	168,232	146,256
Office and other	55,930	113,357	360,039	240,961
Property tax expense	28,259	18,819	84,777	71,025
Rent	48,833	28,598	112,252	55,698
Transfer agent	42,718	7,403	51,708	36,771
Travel and meals	115,220	135,041	256,360	241,746
Utilities	12,140	6,641	25,947	17,463
Wages and salaries	548,420	409,451	1,889,891	1,222,600
	\$ 1,160,789	\$ 907,801	\$3,431,132	\$2,378,413

14. SELLING AND MARKETING EXPENSE

	Three mon	Three months ended December 31,		Nine months ended	
	Decemb			per 31,	
	2019	2018	2019	2018	
Advertising	\$ 55,517	\$ 169,536	\$ 273,403	\$ 340,336	
Branding	-	54,488	146,238	159,718	
Digital marketing	2,505	7,668	10,686	18,922	
Investor relations	70,410	66,261	271,929	214,920	
Public relations	8,943	31,478	97,470	102,008	
Trade shows	20,687	7,785	120,493	50,224	
Sales administration costs	16,703	33,490	34,851	39,355	
Travel and meals	54,856	11,382	119,512	139,864	
Wages	136,693	126,570	345,644	285,134	
	\$ 366,314	\$ 508,660	\$1,420,224	\$ 1,350,480	

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

15. FINANCIAL INSTRUMENTS AND RISK

Fair Value

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- a) Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- b) Level 2 Inputs other than quoted prices that are observable for assets or liabilities, either directly or indirectly;
- c) Level 3 Inputs for assets and liabilities that are not based on observable market data.

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. The carrying value of receivables and accounts payable and accrued liabilities approximates their fair value because of the short-term nature of these instruments.

The fair values of cash and cash equivalents and short-term investments are measured based on level 1 inputs of the fair value hierarchy.

Risk

The Company is exposed to various risks through its financial instruments and has a risk management framework to monitor, evaluate and manage these risks. The following analysis provides information about the Company's risk exposure and concentration as of December 31, 2019:

Credit risk

Credit risk refers to the risk that another entity will default on its contractual obligations which will result in a loss for the Company. At December 31, 2019, the Company's exposure to credit risk consists of the carrying value of cash and cash equivalents, and receivables. The Company limits its credit exposure on cash by holding its deposits with established financial institutions. Accounts receivable consists of trade accounts receivable and miscellaneous receivables. The Company mitigates the risk of default of accounts receivable by assessing the credit worthiness of customers prior to sale and shipment of inventory.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

15. FINANCIAL INSTRUMENTS AND RISK (CONTINUED)

Liquidity risk

Liquidity risk arises from our general and capital financing needs with respect to future growth. Liquidity risk could arise if the Company encounters difficulty in meeting future obligations with financial liabilities. As at December 31 2019, the Company has cash and cash equivalents of \$410,574 (March 31, 2019 - \$4,391,072) to settle current liabilities of \$4,265,641 (March 31, 2019 - \$3,659,829). The Company also has short-term investments of \$57,500 as well as \$250,000 of cash which is set aside as restricted cash (Note 9). The Company has planning, budgeting and forecasting processes to help determine its funding requirements to meet various contractual and other obligations and to manage liquidity risk.

Currency risk

The operating results and financial position of the Company are reported in Canadian dollars. The Company is exposed to currency risk arising from the translation of its European subsidiary's operations and to currency transaction risk as some of the Company's financial instruments are denominated in U.S. dollars. The results of the Company's operations are subject to currency translation and transaction risks.

The Company's main risk is associated with fluctuations in Canadian and U.S. dollars and Euros. Assets and liabilities are translated based on the Company's foreign currency translation policy. The Company has determined that, with other variables unchanged, the effect of a 10% increase in the Canadian dollar as at December 31, 2019:

- against the Euro on its net European operations, and
- against the U.S. dollar on financial assets and liabilities, including cash, accounts receivable, accounts payables and accrued liabilities denominated in U.S. dollars

would result in a decrease of approximately \$81,000 to the net loss and comprehensive loss for the nine months ended December 31, 2019 (2018 – increase of approximately \$44,000). The inverse effect would result if the Canadian dollar weakened by 10% against the Euro and U.S. dollar.

At December 31, 2019, the Company had no hedging agreements in place with respect to foreign exchange rates as the Company's operations provide a natural hedge. Certain operational costs are denominated in U.S. dollars and funded directly from the Company's U.S. funds. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.

Interest rate risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. In seeking to minimize the risk from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. As at December 31, 2019, the Company did not have any liabilities that bear interest at rates fluctuating with the prime rate.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

16. CAPITAL MANAGEMENT

Capital Management

The Company's capital includes share capital, cash, the convertible note payable, and the accumulated deficit. The Company's objectives when managing capital are to safeguard the entity's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders. The Company manages the capital structure and makes adjustments in light of changes in economic conditions and the risk characteristics of the underlying assets. The Company may issue new shares in order to meet its financial obligations. The Company has not changed its approach to capital management during the three months ended December 31, 2019.

17. COMMITMENTS

The Company had the following commitments as of December 31, 2019:

- 1. The Company has an employment agreement with a senior executive which includes provision for severance pay if the individual is terminated without cause or due to a change in control. The Company incurs the following obligation based on the salary agreed to:
 - a. Terminated prior to September 10, 2020 \$195,000 plus accrued bonus; or
 - b. Terminated after September 10, 2020 \$292,500 plus accrued bonus.
- 2. The Company has an employment agreement with a senior executive which includes provision for severance pay if the individual is terminated without cause or due to a change in control. The Company incurs the following obligation based on the salary agreed to:
 - a. Terminated prior to April 29, 2020 \$195,000 plus accrued bonus; or
 - b. Terminated after April 29, 2020 \$292,500 plus accrued bonus.
- 3. The Company has an employment agreement with a senior executive which includes provision for severance pay if the individual is terminated without cause or due to a change in control. The Company incurs the following obligation based on the salary agreed to:
 - a. Terminated prior to May 24, 2020 \$195,000 plus accrued bonus; or
 - b. Terminated after May 24, 2020 \$292,500 plus accrued bonus.

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

18. SEGMENTED INFORMATION

Operating segmented information

As at December 31, 2019, the Company had two reportable segments, being the sale of hemp-based nutrition for pets ("Pet"), the planned sale of cannabis under the Cannabis Act, ("Cannabis") as well as the parent, True Leaf Brands Inc. ("Corporate"). The Company has identified these reporting segments based on the internal reports reviewed and used by the Chief Executive Officer, its chief decision maker, in allocating resources and assessing performance.

Operating segmented information is presented as follows:

A + D1 21 2010	Pet		C1.'		C	T.4.1
As at December 31, 2019			Cannabis		Corporate	Total #2 246 549
Current assets	\$1,554,508		\$373,024		\$319,016	\$2,246,548
Non-current assets	248,372		11,134,894		257,013	11,640,279
Liabilities	(816,838)		(54,472)		(5,238,854)	(6,110,164)
Net assets	\$986,042		\$11,453,446		\$(4,662,825)	\$7,776,663
·						
For the nine-months ended						
December 31, 2019	*****					*****
Revenues	\$1,554,884	\$	54,402	\$	-,	\$1,612,449
Gross profit	674,760		54,402		3,163	732,325
Operating expenses	(2,587,231)		(394,241)		(3,651,355)	(6,632,827)
Loss from operations	\$(1,912,471)		\$(339,839)		\$(3,648,192)	\$(5,900,502)
As at March 31, 2019	Pet		Cannabis		Corporate	Total
Current assets	\$ 856,128		\$ 441,127		\$ 4,532,871	\$5,830,126
Non-current assets	258,867		11,007,922		250,000	11,516,789
Liabilities	(294,082)		(790,595)		(4,383,208)	(5,467,885)
Net assets	\$ 820,913		\$10,658,454		\$ 399,663	\$11,879,030
For the three-months ended						
December 31, 2019						
	Pet		Cannabis		Corporate	Total
Revenues	\$ 433,475	\$	54,402	\$	3,163	\$ 491,040
Gross profit	111,797	-	54,402	*	3,163	169,362
Operating expenses	(758,530)		(142,885)		(1,274,461)	(2,175,876)
Loss from operations	\$(646,733)		\$(88,483)		\$(1,271,298)	\$(2,006,515)

Notes to Condensed Interim Consolidated Financial Statements For the Nine-Month Period Ended December 31, 2019

(Expressed in Canadian dollars)

18. SEGMENTED INFORMATION (CONTINUED)

Geographic segmented information

The Company operates in two main geographic locations, North America and Europe, selling hemp-based nutrition for pets in North America and Europe, which has accounted for all of the Company's revenues since its inception.

As at December 31, 2019	North America	Europe	Total
Current assets	\$2,032,438	\$214,110	\$2,246,548
Non-current assets	11,609,833	30,446	11,640,279
Liabilities	(5,938,781)	(171,383)	(6,110,164)
Total net assets	\$7,703,490	\$73,173	\$7,776,663
For the nine-months ended			
December 31, 2019			
Revenues	\$1,288,949	\$323,500	\$1,612,449
Gross profit	610,318	122,007	732,325
Operating expenses	(6,174,780)	(458,047)	(6,632,827)
Loss from operations	\$(5,564,462)	\$(336,040)	\$(5,900,502)
As at March 31, 2019	North America	Europe	Total
Current assets	\$5,663,668	\$166,458	\$5,830,126
Non-current assets	11,474,822	41,967	11,516,789
Liabilities	(5,398,959)	(68,926)	(5,467,885)
Total net assets	\$11,739,531	\$139,499	\$11,879,030
For the three-months ended			
December 31, 2019			
Revenues	\$387,738	\$103,302	\$491,040
Gross profit	181,796	(12,434)	169,362
Operating expenses	(2,119,450)	(56,427)	(2,175,877)
Loss from operations	\$(1,937,654)	(\$68,861)	\$(2,006,532)